Year archive

CHIMERIC THERAPEUTICS LIMITED — 2023 filings

All 104 regulatory filings released by CHIMERIC THERAPEUTICS LIMITED (CHM) in 2023, sourced directly from the official regulator.

104 Filings

2023 Period

2023 filings (104)

Filing	Released	Lang
Notification regarding unquoted securities - CHM 5 pages 26.3KB Share Issue/Capital Change	2023-12-21	English
Application for quotation of securities - CHM 6 pages 28.0KB Capital/Financing Update	2023-12-21	English
Notice under section 708A 1 page 215.0KB Capital/Financing Update	2023-12-21	English
Chimeric to present at Biotech Showcase at JPM week 2 pages 182.8KB Investor Presentation	2023-12-20	English
ADVENT-AML clinical trial GMP manufacturing complete 3 pages 210.4KB Regulatory Filings	2023-12-18	English
Application for quotation of securities - CHM 10 pages 38.4KB Capital/Financing Update	2023-12-14	English
Notification regarding unquoted securities - CHM 7 pages 30.7KB Share Issue/Capital Change	2023-12-14	English
Notification regarding unquoted securities - CHM 7 pages 30.0KB Share Issue/Capital Change	2023-12-14	English
Notification of cessation of securities - CHM 4 pages 24.5KB Share Issue/Capital Change	2023-12-14	English
Change of Director's Interest Notice JC 3 pages 212.8KB Director's Dealing	2023-12-14	English
Notice under section 708A 1 page 215.0KB Regulatory Filings	2023-12-14	English
Change of Director's Interest Notice PHa 2 pages 219.1KB Director's Dealing	2023-12-13	English
Completion of Entitlement Offer 2 pages 174.3KB Capital/Financing Update	2023-12-06	English
Application for quotation of securities - CHM 6 pages 27.9KB Share Issue/Capital Change	2023-12-06	English
Positive in vitro data for CHM 1301 CAR NK cells-supplement 4 pages 239.6KB Regulatory Filings	2023-11-27	English
Program update webinar with executive team - Tuesday 28 Nov 2 pages 221.0KB Investor Presentation	2023-11-23	English
Positive in vitro data for CHM 1301 CAR NK cells 3 pages 232.4KB Regulatory Filings	2023-11-22	English
Amended Constitution 55 pages 971.6KB Governance Information	2023-11-21	English
Phase 1B ADVENT-AML trial to be presented at ASH meeting 3 pages 234.2KB Regulatory Filings	2023-11-19	English
Entitlement Offer closing date extended to 30 November 2023 2 pages 207.8KB Capital/Financing Update	2023-11-14	English
Update - Proposed issue of securities - CHM 6 pages 31.4KB Capital/Financing Update	2023-11-14	English
Presentation to Annual General Meeting 13 pages 1.9MB AGM Information	2023-11-13	English
Results of Annual General Meeting 2 pages 280.5KB Declaration of Voting Results & Voting Rights Announcements	2023-11-13	English
Application for quotation of securities - CHM 6 pages 28.0KB Capital/Financing Update	2023-11-02	English
Notice under section 708A 1 page 214.7KB Capital/Financing Update	2023-11-02	English
Entitlement Offer Documents 43 pages 4.6MB Capital/Financing Update	2023-11-01	English
1st patient dosed in Phase 1b recurrent glioblastoma trial 3 pages 210.7KB Regulatory Filings	2023-11-01	English
FDA clearance of IND for CHM 2101 3 pages 210.8KB Capital/Financing Update	2023-10-30	English
Quarterly Activities/Appendix 4C Cash Flow Report 14 pages 953.8KB Interim / Quarterly Report	2023-10-30	English
Entitlement Offer to raise approximately $10 million 4 pages 274.8KB Capital/Financing Update	2023-10-24	English
Proposed issue of securities - CHM 6 pages 31.7KB Capital/Financing Update	2023-10-24	English
Investor Presentation - Entitlement Offer 32 pages 3.5MB Investor Presentation	2023-10-24	English
Proposed issue of securities - CHM 5 pages 27.1KB Capital/Financing Update	2023-10-24	English
Entitlement Offer cleansing notice under section 708AA 3 pages 248.0KB Capital/Financing Update	2023-10-24	English
Entitlement Offer update to timetable 2 pages 222.8KB Capital/Financing Update	2023-10-24	English
New data for Phase 1A CLTX CAR T brain cancer clinical trial 8 pages 486.4KB Capital/Financing Update	2023-10-22	English
Trading Halt 2 pages 588.9KB Regulatory Filings	2023-10-19	English
Notice of Annual General Meeting/Proxy Form 39 pages 935.7KB AGM Information	2023-10-15	English
Application for quotation of securities - CHM 6 pages 28.0KB Capital/Financing Update	2023-10-03	English
Notice under section 708A 1 page 236.9KB Regulatory Filings	2023-10-03	English
Annual Report to shareholders 102 pages 2.4MB Annual Report	2023-09-27	English
Corporate Governance Statement 7 pages 212.8KB Governance Information	2023-09-27	English
Appendix 4G 12 pages 354.3KB Regulatory Filings	2023-09-27	English
ESG Report 10 pages 461.3KB Environmental & Social Information	2023-09-27	English
Notification regarding unquoted securities - CHM 5 pages 26.3KB Share Issue/Capital Change	2023-09-18	English
Agreement with MD Anderson for Phase 1B CHM 0201 AML study 4 pages 296.4KB Regulatory Filings	2023-09-12	English
EGM Presentation 13 pages 1.8MB Investor Presentation	2023-09-12	English
Results of Extraordinary General Meeting 2 pages 273.7KB Declaration of Voting Results & Voting Rights Announcements	2023-09-12	English
Initial Director's Interest Notice ES 2 pages 221.0KB Director's Dealing	2023-08-30	English
Final Director's Interest Notice CE 2 pages 253.1KB Director's Dealing	2023-08-30	English
Appendix 4E and Preliminary Final Report 31 pages 1.1MB Annual Report	2023-08-30	English
Non-Executive Director Board Changes 2 pages 182.6KB Board/Management Information	2023-08-29	English
Dosing completion in Phase 1A brain cancer clinical trial 3 pages 210.3KB Regulatory Filings	2023-08-28	English
Late lodgement of Appendix 3Y 4 pages 381.8KB Director's Dealing	2023-08-27	English
Chimeric to receive A$4.4 million introduction fee 2 pages 180.1KB Capital/Financing Update	2023-08-15	English
Notice of Extraordinary General Meeting/Proxy Form 25 pages 996.6KB AGM Information	2023-08-14	English
Positive data - CHM 0301 next-gen armoured NK cell platform 3 pages 286.2KB Regulatory Filings	2023-08-14	English
Resignation of Director 2 pages 179.5KB Board/Management Information	2023-08-02	English
Final Director's Interest Notice 2 pages 240.4KB Director's Dealing	2023-08-02	English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 1.4MB Interim / Quarterly Report	2023-07-30	English
Patent allowance for Chlorotoxin in Japan 2 pages 180.7KB Regulatory Filings	2023-07-26	English
Change of Director's Interest Notice x 6 14 pages 465.9KB Director's Dealing	2023-07-16	English
Initial Director's Interest Notice PH 2 pages 195.6KB Director's Dealing	2023-07-16	English
Final Director's Interest Notice LC 2 pages 235.4KB Director's Dealing	2023-07-16	English
Change in substantial holding PH 3 pages 293.3KB Major Shareholding Notification	2023-07-16	English
Application for quotation of securities - CHM 6 pages 27.7KB Share Issue/Capital Change	2023-07-13	English
Notification regarding unquoted securities - CHM 7 pages 29.3KB Share Issue/Capital Change	2023-07-13	English
Notice under section 708A 1 page 235.5KB Regulatory Filings	2023-07-13	English
Board Changes Director 2 pages 122.0KB Board/Management Information	2023-07-11	English
Results of Extraordinary General Meeting 2 pages 213.4KB Declaration of Voting Results & Voting Rights Announcements	2023-06-28	English
Application for quotation of securities - CHM 6 pages 28.0KB Capital/Financing Update	2023-06-28	English
Notice under section 708A 1 page 236.4KB Regulatory Filings	2023-06-28	English
Share purchase plan completed 1 page 164.7KB Capital/Financing Update	2023-06-22	English
Application for quotation of securities - CHM 6 pages 27.7KB Capital/Financing Update	2023-06-22	English
CHM secures up to A$12.6m through SPP and placements 7 pages 309.3KB Capital/Financing Update	2023-06-22	English
Proposed issue of securities - CHM 5 pages 27.6KB Capital/Financing Update	2023-06-22	English
Proposed issue of securities - CHM 6 pages 29.7KB Capital/Financing Update	2023-06-22	English
Application for quotation of securities - CHM 6 pages 28.6KB Share Issue/Capital Change	2023-06-22	English
Chimeric's Phase 1B glioblastoma trial presented at ASCO23 5 pages 1.1MB Regulatory Filings	2023-06-05	English
Launch of new Phase 1B Glioblastoma clinical trial 3 pages 226.3KB Regulatory Filings	2023-06-04	English
Share purchase plan (SPP) - closing date extended 1 Capital/Financing Update	2023-06-01	English
Update - Proposed issue of securities - CHM 7 pages 32.1KB Capital/Financing Update	2023-06-01	English
Notice of Extraordinary General Meeting/Proxy Form 22 pages 633.1KB Proxy Solicitation & Information Statement	2023-05-30	English
SPP Cleansing Notice 1 page 210.7KB Capital/Financing Update	2023-05-22	English
SPP offer documents issued to shareholders 10 pages 552.8KB Capital/Financing Update	2023-05-22	English
BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP 4 pages 232.1KB Capital/Financing Update	2023-05-14	English
Proposed issue of securities - CHM 5 pages 27.3KB Capital/Financing Update	2023-05-14	English
Proposed issue of securities - CHM 7 pages 32.4KB Capital/Financing Update	2023-05-14	English
New CLTX CAR technology patent protection in India & Israel 3 pages 199.4KB Regulatory Filings	2023-04-27	English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 1.2MB Interim / Quarterly Report	2023-04-27	English
Phase 1B brain cancer clinical trial approved for initiation 4 pages 320.9KB Regulatory Filings	2023-04-25	English
CHM to host CAR T Cell Therapies Educational Webinar 2 pages 197.5KB Regulatory Filings	2023-04-10	English
CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation 3 pages 246.8KB Regulatory Filings	2023-04-02	English
Positive pre-IND meeting with FDA for Phase 1 CAR T study 3 pages 201.6KB Regulatory Filings	2023-03-20	English
Chimeric to present at virtual healthcare conference 2 pages 175.1KB Investor Presentation	2023-03-14	English
Completion of Viral Vector Manufacturing for Phase 1 trial 3 pages 201.5KB Capital/Financing Update	2023-03-08	English
Fourth dose cohort initiated in CHM 1101 Phase 1 trial 3 pages 204.5KB Regulatory Filings	2023-03-01	English
Appendix 4D and Half Year Report 36 pages 1.8MB Interim / Quarterly Report	2023-02-27	English
CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE 2 pages 176.9KB Capital/Financing Update	2023-02-13	English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 1.2MB Interim / Quarterly Report	2023-01-30	English
Follow up period completed for 3rd cohort in CHM 1101 trial 3 pages 202.8KB Regulatory Filings	2023-01-22	English
1st patient dosed in CHM 0201 Vactosertib trial 3 pages 225.8KB Regulatory Filings	2023-01-18	English
Application for quotation of securities - CHM 6 pages 27.3KB Share Issue/Capital Change	2023-01-17	English
Release of Securities from Escrow 1 page 134.4KB Regulatory Filings	2023-01-09	English